Select Page

WILMINGTON, Del., Oct. 05, 2020 (GLOBE NEWSWIRE) — Rigrodsky & Long, P.A. announces that it is investigating Eidos Therapeutics, Inc. (“Eidos”) (NASDAQ GS: EIDX) regarding possible breaches of fiduciary duties and other violations of law related to Eidos’ agreement to be acquired by BridgeBio Pharma, Inc. (“BridgeBio”) (NASDAQ GS: BBIO). Under the terms of the agreement, Eidos’ shareholders will receive either 1.85 shares of BridgeBio common stock or $73.26 in cash per share.